Skip to content

Effect of Non-alcoholic Beer in Cirrhosis

Effect of a Multifactorial Intervention (Non-alcoholic Beer, Diet and Exercise) on Endothelial Function, Nutritional Status and Quality of Life in Patients With Cirrhosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04041115
Acronym
LFN-NAB
Enrollment
42
Registered
2019-08-01
Start date
2016-01-31
Completion date
2022-08-15
Last updated
2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Nutritional Status, Quality of Life

Keywords

cirrhosis, nutrition, sarcopenia, non-alcoholic beer

Brief summary

The implementation of nutritional strategies targeting several variables at once could benefit patients with cirrhosis. Non-alcoholic beer has different compounds derived from hops that exert antioxidant, anti-inflammatory and nutritional properties. The aim of this study is to evaluate the effect of diet + exercise and non-alcoholic beer on nutritional status, endothelial function and quality of life in patients with cirrhosis.

Interventions

DIETARY_SUPPLEMENTNon-alcoholic beer

Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.

OTHERcontrol

Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.

Sponsors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Liver Cirrhosis of any aetiology (liver biopsy or a combination of clinical and biochemical variables plus evidence of portal hypertension); without decompensation during the past month; serum creatinine \<1.5 mg%; able to attend the appointed visits and willing to participate in the study.

Exclusion criteria

* Severe concomitant cardiopulmonary diseases; decompensated type 2 Diabetes Mellitus, insulin use or proliferative diabetic retinopathy; orthopedic or osteomuscular limitations; any type of cancer; primary sclerosing cholangitis and inflammatory bowel disease.

Design outcomes

Primary

MeasureTime frameDescription
Nutritional status8 weeksimprovement in impedance-derived phase angle (PhA)
Endothelial function8 weeksimprovement in flow-mediated dilation (brachial artery)
Endothelial dysfunction8 weeksimprovement in serum markers of endothelial function (v.gr. nitric oxide, NO; prostacyclin, PGI2, etc.)
Quality of life questionnaire8 weeksImprovement in quality of life questionnaire CLDQ (chronic liver disease questionnaire)
Changes in the heterogeneity of gut Microbiota8 weeksChanges in the heterogeneity of fecal microbiota in terms of bacterial diversity will be assessed

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026